- Clinical Trials
- February 2024
- 180 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Report
- October 2022
- 270 Pages
Global
From €3619EUR$3,750USD£3,105GBP
Trexall is a brand name for the drug methotrexate, an immune disorder drug used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease. It works by suppressing the immune system, which helps reduce inflammation and pain. It is also used to treat certain types of cancer, such as leukemia and lymphoma. Trexall is available in both oral and injectable forms, and is usually taken once a week.
The Trexall market is a competitive one, with a number of generic and branded versions of the drug available. The market is largely driven by the increasing prevalence of autoimmune diseases, as well as the need for more effective treatments. As such, the market is expected to continue to grow in the coming years.
Some of the major players in the Trexall market include Pfizer, Novartis, Merck, and Sanofi. Other companies, such as Mylan, Teva, and Sun Pharmaceuticals, also offer generic versions of the drug. Show Less Read more